

## Drug Policy:

# Margenza™ (margetuximab-cmkb)

<b>POLICY NUMBER</b> UM ONC_1420	<b>SUBJECT</b> Margenza™ (margetuximab-cmkb)		<b>DEPT/PROGRAM</b> UM Dept	<b>PAGE 1 of 3</b>
<b>DATES COMMITTEE REVIEWED</b> 02/10/21, 05/12/21, 11/15/21, 03/09/22, 05/11/22, 02/08/23, 03/08/23	<b>APPROVAL DATE</b> March 8, 2023	<b>EFFECTIVE DATE</b> March 31, 2023	<b>COMMITTEE APPROVAL DATES</b> 02/10/21, 05/12/21, 11/15/21, 03/09/22, 05/11/22, 02/08/23, 03/08/23	
<b>PRIMARY BUSINESS OWNER: UM</b>		<b>COMMITTEE/BOARD APPROVAL</b> Utilization Management Committee		
<b>URAC STANDARDS</b> HUM v8: UM 1-2; UM 2-1	<b>NCQA STANDARDS</b> UM 2		<b>ADDITIONAL AREAS OF IMPACT</b>	
<b>CMS REQUIREMENTS</b>	<b>STATE/FEDERAL REQUIREMENTS</b>		<b>APPLICABLE LINES OF BUSINESS</b> All	

### I. PURPOSE

To define and describe the accepted indications for Margenza (margetuximab-cmkb) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

New Century Health (NCH) is responsible for processing all medication requests from network ordering providers. Medications not authorized by NCH may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

### II. INDICATIONS FOR USE/INCLUSION CRITERIA

#### A. Continuation requests for a not-approvable medication shall be exempt from this NCH policy provided:

1. The requested medication was used within the last year, **AND**
2. The member has not experienced disease progression and/or no intolerance to the requested medication, **AND**
3. Additional medication(s) are not being added to the continuation request.

#### B. Metastatic HER-2 + Breast Cancer

1. NOTE: Per NCH Policy, Margenza (margetuximab), with or without chemotherapy, is Not Approvable for the treatment of metastatic HER2 positive breast cancer. This Policy Position is supported by data from the Phase 3 SOPHIA trial (please see reference below) which demonstrated no significant Overall Survival benefit of the above regimen over [trastuzumab + chemotherapy]. Please refer to the alternative agents/regimens recommended by NCH, including but not limited to regimens at <http://pathways.newcenturyhealth.com>.

### III. EXCLUSION CRITERIA

- A. Disease progression while taking Margenza (margetuximab-cmkb).
- B. Concurrent use with another anti-HER2 agent, e.g., Perjeta (pertuzumab).
- C. Dosing exceeds single dose limit of Margenza (margetuximab-cmkb) 15 mg/kg.
- D. Investigational use of Margenza (margetuximab-cmkb) with an off-label indication that is not sufficient in evidence or is not generally accepted by the medical community. Sufficient evidence that is not supported by CMS recognized compendia or acceptable peer reviewed literature is defined as any of the following:
  1. Whether the clinical characteristics of the patient and the cancer are adequately represented in the published evidence.
  2. Whether the administered chemotherapy/biologic therapy/immune therapy/targeted therapy/other oncologic therapy regimen is adequately represented in the published evidence.
  3. Whether the reported study outcomes represent clinically meaningful outcomes experienced by patients. Generally, the definitions of Clinically Meaningful outcomes are those recommended by ASCO, e.g., Hazard Ratio of less than 0.80 and the recommended survival benefit for OS and PFS should be at least 3 months.
  4. Whether the experimental design, considering the drugs and conditions under investigation, is appropriate to address the investigative question. (For example, in some clinical studies, it may be unnecessary or not feasible to use randomization, double blind trials, placebos, or crossover).
  5. That non-randomized clinical trials with a significant number of subjects may be a basis for supportive clinical evidence for determining accepted uses of drugs.
  6. That case reports are generally considered uncontrolled and anecdotal information and do not provide adequate supportive clinical evidence for determining accepted uses of drugs.
  7. That abstracts (including meeting abstracts) without the full article from the approved peer-reviewed journals lack supporting clinical evidence for determining accepted uses of drugs.

### IV. MEDICATION MANAGEMENT

- A. Please refer to the FDA label/package insert for details regarding these topics.

### V. APPROVAL AUTHORITY

- A. Review – Utilization Management Department
- B. Final Approval – Utilization Management Committee

### VI. ATTACHMENTS

- A. None

## VII. REFERENCES

- A. Rugo HS, et al. SOPHIA Trial. Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. *JAMA Oncol.* 2021 Apr 1;7(4):573-584.
- B. Rugo HS, Im SA, Cardoso F, et al: Phase III SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: Second interim overall survival analysis. 2019 San Antonio Breast Cancer Symposium. Abstract GS1-02. Presented December 11, 2019.
- C. Rugo HS, Im SA, Shaw Wright GL, et al: SOPHIA primary analysis: A phase 3 study of margetuximab + chemotherapy (C) versus trastuzumab + C in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies. 2019 ASCO Annual Meeting. Abstract 1000. Presented June 4, 2019.
- D. Margenza prescribing information. MacroGenics, Inc. Rockville, MD 2022.
- E. Clinical Pharmacology Elsevier Gold Standard 2023.
- F. Micromedex® Healthcare Series: Micromedex Drugdex Ann Arbor, Michigan 2023.
- G. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium 2023.
- H. AHFS Drug Information. American Society of Health-Systems Pharmacists or Wolters Kluwer Lexi-Drugs Bethesda, MD 2023.
- I. Ellis LM, et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. *J Clin Oncol.* 2014 Apr 20;32(12):1277-80.
- J. Medicare Benefit Policy Manual Chapter 15 Covered Medical and Other Health Services: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf>.
- K. Current and Resolved Drug Shortages and Discontinuations Reported to the FDA: <http://www.accessdata.fda.gov/scripts/drugshortages/default.cfm>.
- L. NCQA UM 2023 Standards and Elements.